Skip to content

Depression: all studies

Page 621 of 1,035: studies 6,201 to 6,210 of 10,348, newest first. Back to the depression overview

Research

Ketamine - An Imperfect Wonder Drug?

Biochemical Pharmacology November 1, 2024 Tanner Magruder, Marielle Isenhart, Maximillian V Striepe et al. 8 citations

Ketamine is a potent sedative and dissociative anesthetic agent that has been used clinically for over 50 years since it was first developed in the 1960 s as an alternative to phencyclidine (PCP). When compared to PCP, ketamine exhibited a much lower incidence of severe side effects, including hallucinations, leading to its increased popularity in clinical practice. Ketamine was initially used...

KETAMINE: Neural- and network-level changes.

Neuroscience November 1, 2024 Vishal Bharmauria, Hamidreza Ramezanpour, Afef Ouelhazi et al.

Ketamine is a widely used clinical drug that has several functional and clinical applications, including its use as an anaesthetic, analgesic, anti-depressive, anti-suicidal agent, among others. Among its diverse behavioral effects, it influences short-term memory and induces psychedelic effects. At the neural level across different brain areas, it modulates neural firing rates, neural tuning,...

How Should We Expand Access to Psychedelics While Maintaining an Environment of Peace and Safety?

AMA journal of ethics November 1, 2024 Zachary J Verne, Jeffrey S Zabinski 1 citation

Psychedelics have long been used by individuals seeking peace and a sense of wellness. This article examines widespread adoption of ketamine as a proxy for psychedelics. For ketamine, there is a need to protect vulnerable persons from exploitation that should be balanced against risks of hypermedicalization. This article suggests strategies for striking such a balance, including by carefully...

DOI: 10.1001/amajethics.2024.868 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Ketamine clinics Medical safety protocols Mental health treatment +1

Psychoactive substances for the treatment of neuropsychiatric disorders.

Asian Journal of Psychiatry November 1, 2024 Zifan Zhen, Xueqiang Sun, Shiying Yuan et al. 8 citations

In the contemporary landscape of psychiatric medicine, critical advancements have been noted in the utilization of psychoactive substances such as hallucinogens, 3,4-methylenedioxymethamphetamine (MDMA), and ketamine for the treatment of severe mental health disorders. This review provides a detailed evaluation of these substances, focusing on their mechanisms of action and the profound...

DOI: 10.1016/j.ajp.2024.104193 (opens in new tab) Full text (opens in new tab) Ketamine MDMA Neuropsychiatric disorders Psychedelics hallucinogens +6

Optimized psilocybin production in tryptophan catabolism‐repressed fungi

Microbial Biotechnology November 1, 2024 Slavica Janevska, Sophie Weiser, Ying Huang et al. 13 citations

Abstract The high therapeutic potential of psilocybin, a prodrug of the psychotropic psilocin, holds great promise for the treatment of mental disorders such as therapy‐refractory depression, alcohol use disorder and anorexia nervosa. Psilocybin has been designated a ‘Breakthrough Therapy’ by the US Food and Drug Administration, and therefore a sustainable production process must be established...

DOI: 10.1111/1751-7915.70039 (opens in new tab) Psilocybin Tryptamine Aspergillus nidulans Biochemistry +1

Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience

BJPsych Open November 1, 2024 Mourad Wahba, Caroline Hayes, Maartje Kletter et al. 6 citations

Background Psilocybin is being investigated as a treatment for a myriad of disorders, including treatment-resistant depression. The main focus has been on positive effects, with little attention paid to negative outcomes, especially in clinical settings. Quantitative methodology limits further exploration of such events and can also miss improvements not captured on rating scales. Aims To...

DOI: 10.1192/bjo.2024.768 (opens in new tab) Full text (opens in new tab) Psilocybin Suicidal ideation Adverse effect Thematic analysis +3

Harmonizing Body and Mind

Advances in Educational Technologies and Instructional Design October 31, 2024 Ranjit Barua

The combination of yoga and mindfulness meditation is examined in this article as a comprehensive strategy for improving mental health. We explore how these traditional practices synergistically harmonize the body and mind by looking at their origins, guiding principles, and potential for therapeutic benefits. People can promote inner calm and resilience while reducing symptoms of stress,...

Evaluating the mobile Mantram Repetition Program for veterans with PTSD: A multimethod randomized feasibility trial of self-directed versus text support delivery.

Psychological Trauma: Theory, Research, Practice and Policy October 31, 2024 Caitlin L Mclean, Ashley Faytol, Gage Chu et al. 1 citation

While mobile delivery can help increase access to evidence-based treatment for veterans with posttraumatic stress disorder (PTSD), feasibility and acceptability are of concern with the potential for high attrition rates and limited participation. The Mantram Repetition Program (MRP), a meditation-focused approach with documented efficacy for reducing symptoms of PTSD and insomnia, was adapted...

Exploration of attitudes towards the mystical experience in the context of psychedelic assisted psychotherapy amongst psychiatry trainees based in the West of Scotland

Consciousness, Spirituality & Transpersonal Psychology October 31, 2024 Cassie Maguire

Modern clinical trials suggest early evidence for the safety and efficacy of psychedelic assisted psychotherapy (PAP) in domains including addictions, dysphoria related to life-threatening illnesses and depression. Research suggests that the mystical experience (ME) under psychedelics appears to play a key role in positive outcomes. With a growing evidence base, it is possible that PAP may be...

DOI: 10.53074/cstp.2024.70 (opens in new tab) Psychedelic therapy Psychiatry training Mental health treatment Mystical experiences +1

Assessing Mindfulness Barriers: Turkish Validation of the Fears and Resistances to Mindfulness Scale (FRM) via a Bifactor Model Approach

Türk Psikolojik Danışma ve Rehberlik Dergisi October 30, 2024 Mustafa Subaşı, Evgeny N Osin, Hakan Karaman et al.

The Fears and Resistances to Mindfulness Scale (FRM) is a self-report measure to help identify who may fear of, have blocks against, and show resistances to mindfulness. The goal of the present study was to evaluate psychometric properties of the Turkish version of the FRM. The study recruited a sample of 448 participants. Participants completed several instruments including the Fears and...